chevron_leftBack
I
As of 14 June 2026, INVO Fertility, Inc. has a market cap of $1.47M USD, ranking #47834 globally and #6115 in the United States.
It ranks #4240 in the Healthcare sector, and #825 in the Biotechnology industry.
Key Stats
Market Cap
$1.47MUSD
Enterprise Value
$12.78MUSD
Net Income (TTM)
-$14.86MUSD
PB Ratio
-0.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Steven Shum
open_in_new
Founded
2007
Website
nayabiosciences.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 8.4% | 20% | -8.7% | -62% | -79% | -84% |
News
Loading...
NAYA Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NAYA
NAYA Biosciences Inc
ISIN: US44984F6097
Shares Out.:
Shares Outstanding:
666.058K1
Shares Float:
574.132K2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
2.20 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About INVO Fertility, Inc.
INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women’s Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as solid and pediatric tumors; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases. The company also offers INVOcell, a a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
12M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
11M%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
2M%
|
-
|
|
NYSE: IQV
|
$26.3B
2M%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
2M%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
1M%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
3M%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
3M%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
3M%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
3M%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
2M%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
2M%
|
-
|
chevron_leftBack